Therapeutic application of THZ1 was further shown to inhibit patient-derived xenografts (PDXs) of TNBC [32], underscoring the potential of CDK7 inhibition as a promising avenue for the management of this aggressive cancer subtype. The gene discussed is CDK7; the disease is cancer.